Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy.
Marschner N, Rüttinger D, Zugmaier G, Nemere G, Lehmann J, Obrist P, Baeuerle PA, Wolf A, Schmidt M, Abrahamsson PA, Reinhardt C, Heidenreich A. Marschner N, et al. Among authors: ruttinger d. Urol Int. 2010;85(4):386-95. doi: 10.1159/000318055. Epub 2010 Jul 2. Urol Int. 2010. PMID: 20606402 Clinical Trial.
Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies.
Münz M, Murr A, Kvesic M, Rau D, Mangold S, Pflanz S, Lumsden J, Volkland J, Fagerberg J, Riethmüller G, Rüttinger D, Kufer P, Baeuerle PA, Raum T. Münz M, et al. Among authors: ruttinger d. Cancer Cell Int. 2010 Nov 2;10:44. doi: 10.1186/1475-2867-10-44. Cancer Cell Int. 2010. PMID: 21044305 Free PMC article.
Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer.
Schmidt M, Rüttinger D, Sebastian M, Hanusch CA, Marschner N, Baeuerle PA, Wolf A, Göppel G, Oruzio D, Schlimok G, Steger GG, Wolf C, Eiermann W, Lang A, Schuler M. Schmidt M, et al. Among authors: ruttinger d. Ann Oncol. 2012 Sep;23(9):2306-2313. doi: 10.1093/annonc/mdr625. Epub 2012 Feb 21. Ann Oncol. 2012. PMID: 22357251 Free article. Clinical Trial.
An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer.
Schmidt M, Scheulen ME, Dittrich C, Obrist P, Marschner N, Dirix L, Schmidt M, Rüttinger D, Schuler M, Reinhardt C, Awada A. Schmidt M, et al. Among authors: ruttinger d. Ann Oncol. 2010 Feb;21(2):275-282. doi: 10.1093/annonc/mdp314. Epub 2009 Jul 24. Ann Oncol. 2010. PMID: 19633042 Free article. Clinical Trial.
Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial.
Ströhlein MA, Lordick F, Rüttinger D, Grützner KU, Schemanski OC, Jäger M, Lindhofer H, Hennig M, Jauch KW, Peschel C, Heiss MM. Ströhlein MA, et al. Among authors: ruttinger d. Onkologie. 2011;34(3):101-8. doi: 10.1159/000324667. Epub 2011 Feb 18. Onkologie. 2011. PMID: 21358214 Clinical Trial.
Immunotherapy of lung cancer: an update.
Rüttinger D, Winter H, van den Engel NK, Hatz RA, Schlemmer M, Pohla H, Grützner S, Schendel DJ, Fox BA, Jauch KW. Rüttinger D, et al. Onkologie. 2006 Feb;29(1-2):33-8. doi: 10.1159/000090341. Onkologie. 2006. PMID: 16514254 Free article. Review.
67 results